Investment and funding

Antikor’s business model, its research collaborations and ability to leverage the expertise and facilities at both Stevenage BioScience Catalyst and Imperial College, make it a lean, flexible and efficient organisation – and an exciting merger or trade sale opportunity, which will provide an attractive exit for investors.

Following on from its recent strategic alliance with Essex Bio-technology, Antikor is preparing for a Series A funding round, with a target of raising ~$15 million for clinical development of its products providing investors with a signficant return. If you are interested in the investment opportunities described here, please contact us to discuss your interest.